311
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Comparison of Intraocular Antibody Measurement, Quantitative Pathogen PCR, and Metagenomic Deep Sequencing of Aqueous Humor in Secondary Glaucoma Associated with Anterior Segment Uveitis

, MD, PhDORCID Icon, , MM, , PhD, , MS, , MD, PhD, , MD, PhD & , MD, PhD show all
Pages 153-159 | Received 29 Feb 2020, Accepted 28 May 2020, Published online: 18 Aug 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Qilian Sheng, Yanan Sun, Ruyi Zhai, Xintong Fan, Yue Ying & Xiangmei Kong. (2023) 2% Ganciclovir Controlled Posner-Schlossman Syndrome Relapse and Reduced the Chance of Corticosteroid Dependence: A Large Cohort in East China. Ocular Immunology and Inflammation 0:0, pages 1-8.
Read now

Articles from other publishers (2)

Carmen Alba‐Linero, Carlos Rocha‐de‐Lossada, Rahul Rachwani‐Anil, Maite Sainz‐de‐la‐Maza, Gabriel Sena‐Corrales, Vito Romano & Marina Rodríguez‐Calvo‐de‐Mora. (2021) Anterior segment involvement in Epstein–Barr virus: a review. Acta Ophthalmologica 100:5.
Crossref
Matthias Lenglinger, Therese Schick, Dominika Pohlmann & Uwe Pleyer. (2022) Cytomegalovirus-Positive Posner-Schlossman Syndrome: Impact on Corneal Endothelial Cell Loss and Retinal Nerve Fiber Layer Thinning. American Journal of Ophthalmology 237, pages 290-298.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.